Latest News — Page 28

💡 Are digital technologies the future of cardiac rehabilitation?

The latest NICE recommendations unveil seven innovative tools that aim to transform access and adherence for patients with cardiovascular disease. These platforms promise to enhance recovery with personalized support—breaking barriers of traditional programs while gathering crucial evidence over the next three years.

Dive into the details of how these tools can reshape patient care and improve outcomes.

#SyenzaNews #digitalhealth #HealthTech #HealthcareInnovation

Could repurposing off‑patent medicines be the fastest route to new treatments for rare diseases? 💊🔍

An EMA pilot showed tailored scientific advice can help academia turn existing clinical and real‑world data into regulatory‑ready evidence—accelerating access while lowering development costs—yet limited industry engagement means policy incentives are still needed.

Read the full article to see case examples, regulatory lessons, and what changes could scale this approach for rare‑disease patients.

#SyenzaNews #regulatoryaffairs #drugdevelopment #MarketAccess #healthcarepolicy

Are dual-target cell therapies reshaping haematology care? 🔬

AstraZeneca’s largest ASH 2025 presence featured 65 abstracts — including promising Phase I/II data for surovatamig and AZD0120 plus sustained outcomes for Calquence and Ultomiris — pointing to deeper, durable responses and meaningful HEOR implications for access and pricing.

Read the full article to dive into the trial highlights, real-world evidence, and what this could mean for clinicians, payers and patients.

#SyenzaNews #oncology #clinicaltrials #MarketAccess #costeffectiveness

🌍 How is the EU reshaping health technology assessments for the future of cancer treatment?

The HTACG Draft Annual Work Programme for 2026 reveals an ambitious agenda, targeting standardized evaluations across Member States. With a focus on 35 joint clinical assessments for oncology products and groundbreaking plans for advanced therapies, the initiative promises to enhance patient access and boost innovation in healthcare.

Dive deeper into how these changes are set to streamline processes and improve outcomes in the EU health landscape!

#SyenzaNews #oncology #healthcarepolicy 🚀

🌍 Are you ready to rethink how we approach obesity management?

The newly released WHO guideline on GLP-1 obesity therapies marks a significant shift in treating a condition that affects over 1 billion people globally. This groundbreaking document outlines evidence-based recommendations that prioritize safe, equitable access to GLP-1 therapies, all while integrating behavioral support to enhance health outcomes.

Dive into the full article to explore how these advancements could reshape chronic obesity care and promote healthier lives.

#SyenzaNews #GlobalHealth #HealthcareInnovation #HealthTech

Could the EU’s Critical Medicines Act be the turning point for reliable access to essential drugs? 🇪🇺🔒

The proposal targets supply security by diversifying supply chains, boosting EU API production and encouraging joint procurement to keep antibiotics, insulin, vaccines and other critical therapies available. The Council’s procurement changes and industry reactions highlight trade-offs that will reshape pricing, reimbursement and Health Economics assessments across the EU.

Read the full analysis to see what this means for manufacturers, payers and policymakers.

#SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #MarketAccess

Could a new NIST-backed Center reshape U.S. biopharma manufacturing? 🔬🏛️

The Biomanufacturing Excellence Act of 2025 (H.R. 6089) would create a National Biopharmaceutical Manufacturing Center of Excellence with $120M authorized for FY2026 to accelerate flexible manufacturing, standardization, workforce training, and reduce foreign supply-chain dependencies. These changes could lower costs, speed commercialization of biologics, and reshape HEOR and market access calculations.

Read the full article to understand the policy, economic, and industry implications.

#SyenzaNews #biotechnology #HealthEconomics #healthcarepolicy #innovation

💊 Are you ready to see a significant shift in how seniors access affordable medications?

Starting January 1, 2027, Medicare drug price negotiations will bring prices down by an average of 44% on 15 essential treatments for cancer and chronic diseases, translating to an astounding $12 billion in annual savings! This transformative change not only eases the financial burden for 5.3 million beneficiaries but also maintains a balance between affordability and ongoing innovation in healthcare.

Curious to learn more about how these negotiations will impact patient care? Dive into the full article for all the insights!

#SyenzaNews #healthcare #HealthEconomics 🌟

Can Europe speed up multinational trials without sacrificing safety? ⏱️🚀

FAST‑EU brings NCAs and Ethics Committees into a coordinated fast‑track evaluation, integrating ethics opinions from all participating states to deliver predictable timelines and reduce authorization delays. The initiative aims to attract more research investment, strengthen HEOR data, and accelerate patient access to innovative therapies while keeping safety and ethics front and center.

Read the full article to see how FAST‑EU could reshape regulatory pathways and market access strategies.

#SyenzaNews #clinicaltrials #regulatoryaffairs #MarketAccess #innovation

Could continuous glucose monitoring be the new standard for Type 2 diabetes care? 📈

A JAMA Insights review summarizes RCTs and real-world data showing CGM lowers HbA1c (about 0.3% on average), reduces hypoglycemia, and links to improved survival—while AGP reports and real-time alerts make it practical for primary care and population management.

Read the full article to explore the evidence, clinical applications, and reimbursement implications. 🩺

#SyenzaNews #digitalhealth #HealthTech #MarketAccess #costeffectiveness

Can GLP‑1 receptor agonists be the missing link to prevent antipsychotic‑induced weight gain? 💡

JAMA Psychiatry synthesizes RCTs and meta‑analyses showing GLP‑1RAs (liraglutide, semaglutide, exenatide) produce meaningful weight loss and metabolic improvements in patients on second‑generation antipsychotics—often without worsening psychiatric symptoms—and highlights strong psychiatric safety and transdiagnostic efficacy. The piece also makes the health‑economic case for updating guidelines and expanding access to reduce cardiometabolic risk and improve long‑term outcomes.

Explore the full article to review the data, safety profile, and implications for clinical practice and reimbursement. 🔍

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #costeffectiveness

Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬

NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding improved event‑free and overall survival versus blinatumomab, inotuzumab and ponatinib and cost‑effectiveness within NHS thresholds — though it’s not recommended for 18–25s due to pricing vs tisagenlecleucel.

Read the full guidance to see what this means for clinicians, payers and developers.

#SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Can Latin America become a global hub for innovative therapies? 🚀

Bristol Myers Squibb is shifting from country-by-country tactics to a unified regional strategy—backed by 100 active trials across 1,000+ sites, regulatory reliance pathways, and risk‑sharing models—to shorten the five‑year lag after US/EU approvals and scale launches (8 molecules, 16 indications by 2030) that could reach 1.5M patients. This approach ties clinical investment to Health Economics and market access solutions to drive sustainable, equitable impact across oncology, immunology, cardiovascular disease and beyond.

Read the full interview with Constanza Losada to learn how collaboration, digital transformation and HEOR are reshaping access across LATAM.

#SyenzaNews #HealthEconomics #clinicaltrials #MarketAccess #innovation

💡 Are we integrating HEOR insights too late in drug development?

Indranil Bagchi argues for earlier HEOR market access integration before Phase 3, emphasizing the need for payer-specific evidence to improve patient access in an increasingly restrictive landscape. However, his perspective raises critical questions about the potential drawbacks of such approaches.

Dive into this insightful discussion and explore how proactive strategies in early payer engagement could reshape our industry—while also navigating the complexities of market access.

#SyenzaNews #HealthEconomics #MarketAccess

🌟 Have you noticed the rising importance of patient-reported outcomes in clinical trials?

In a recent analysis of trials from 2008 to 2023, there’s a striking trend—usage of patient-reported outcome measures (PROs) has nearly doubled, reflecting a significant shift towards patient-centered research. Tools like EQ-5D and PROMIS are leading the charge, emphasizing the importance of health-related quality of life data.

Dive into this insightful article to explore how these trends are shaping the future of healthcare and decision-making!

#SyenzaNews #HealthEconomics #ClinicalTrials #HealthcareInnovation

Can AI really reduce post‑colonoscopy cancer — or is it just inflating adenoma detection rates? 🔍📊

NICE’s new evidence‑generation plan flags critical data gaps across five AI polyp‑detection tools (CAD EYE, ENDO‑AID, EndoScreener, GI Genius, MAGENTIQ‑COLO), calling for randomized trials and robust real‑world studies to prove benefits for high‑risk lesions, cancer outcomes, and clinical workflows — evidence that will drive NHS adoption and HEOR value models.

Read the full analysis to understand what NICE expects, how companies should respond, and the implications for clinicians, payers, and market access.

#SyenzaNews #AIinHealthcare #HealthEconomics #ai #costeffectiveness